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Background: STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for
metastatic hormone naı¨ve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term
outcomes stratified by metastatic burden for M1 patients.
Methods: We randomly allocated patients in 2 : 1 ratio to standard-of-care (SOC; control group) or SOCþdocetaxel. Metastatic
disease burden was categorised using retrospectively-collected baseline staging scans where available. Analysis used Cox regression
models, adjusted for stratification factors, with emphasis on restricted mean survival time where hazards were non-proportional.
Results: Between 05 October 2005 and 31 March 2013, 1086 M1 patients were randomised to receive SOC (n¼ 724) or
SOCþ docetaxel (n¼ 362). Metastatic burden was assessable for 830/1086 (76%) patients; 362 (44%) had low and 468 (56%)
high metastatic burden. Median follow-up was 78.2months. There were 494 deaths on SOC (41% more than the previous
report). There was good evidence of benefit of docetaxel over SOC on OS (HR¼ 0.81, 95% CI 0.69–0.95, P¼ 0.009) with no
evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P¼ 0.827). Analysis of other
outcomes found evidence of benefit for docetaxel over SOC in failure-free survival (HR¼ 0.66, 95% CI 0.57–0.76, P< 0.001) and
progression-free survival (HR¼ 0.69, 95% CI 0.59–0.81, P< 0.001) with no evidence of heterogeneity of docetaxel effect
VC The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduc-
tion in any medium, provided the original work is properly cited.
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between metastatic burden sub-groups (interaction P> 0.5 in each case). There was no evidence that docetaxel resulted in late
toxicity compared with SOC: after 1 year, G3-5 toxicity was reported for 28% SOC and 27% docetaxel (in patients still on follow-
up at 1 year without prior progression).
Conclusions: The clinically significant benefit in survival for upfront docetaxel persists at longer follow-up, with no evidence
that benefit differed by metastatic burden. We advocate that upfront docetaxel is considered for metastatic hormone naı¨ve
prostate cancer patients regardless of metastatic burden.
Key words: prostate cancer, metastatic, hormone naive, docetaxel, STAMPEDE trial, randomised control trial
Introduction
The primary analysis of STAMPEDE’s ‘docetaxel comparison’,
reporting an improvement in survival, was triggered by reaching a
pre-specified number of control group deaths [1]. The trial team
agreed to update this analysis when there was a meaningful increase
in the number of primary outcome measure events after further
follow-up, expected to occur 3 years later. During that time, the
Intermediate Clinical Endpoints in Cancer of the Prostate surrogacy
work showed that measures based on metastatic progression could
be used as a surrogate for survival in patients presentingwithM0dis-
ease, allowing trials in that setting to achieve increased power sooner
[2]. Given the prognosis for metastatic and non-metastatic patients
is now very different and that other trials of first-line docetaxel
have kept metastatic and non-metastatic patients separate, the
STAMPEDE team agreed that the long-term follow-up results would
be analysed separately for these two groups of patients.
Since that initial STAMPEDE report, first-line systemic combin-
ation treatment options given with ADT in metastatic hormone
naı¨ve prostate cancer (mHNPC) have expanded to include abira-
terone, enzalutamide and apalutamide as well as docetaxel [1, 3–8].
However there is still controversy about patient stratification and
selection for treatment. Metastatic burden sub-group analyses of
the CHAARTED and GETUG-15 trials have led some to conclude
that docetaxel should not be given as a first-line treatment of
patients presenting with ‘low metastatic burden’ disease [3, 9–11].
This represents40% of patients presenting with de novomHNPC
[12, 13]. These were retrospective analyses of relatively small sub-
groups of these trials and a number of groups have not been per-
suaded by these exploratory retrospective analyses. Reflecting this
uncertainty, major treatment guidelines offer conflicting advice
about whether all metastatic patients should receive combination
treatment or whether this should be restricted only to those with
‘high-burden’, as specified in the CHAARTED trial [11, 14–16].
To address the hypothesis raised by CHAARTED, bone scans
from the M1 docetaxel comparison cohort were collected retro-
spectively to determine the metastatic burden for STAMPEDE
patients (independently of treatment assignment and outcome)
and to undertake a stratified sub-group analysis. Outcome for the
sub-groups categorised by individual metastatic burden was then
determined using the extended patient follow-up now available
in the STAMPEDEM1 cohort.
Materials and methods
Study design
The multi-arm, multi-stage STAMPEDE trial enrols patients with
advanced high-risk or metastatic prostate cancer. Between 05 October
2005 and 31 March 2013, men with newly diagnosed metastatic prostate
cancer were randomised on a 2 : 1 basis either to a standard-of-care
(SOC) control group (‘Control’) or SOCþ docetaxel treatment group
(‘docetaxel’) [1]. SOC inM1 patients comprised long-term androgen de-
privation therapy (ADT), the intervention being lifelong ADT and six
cycles of docetaxel at standard dose. Randomisation followed a mini-
misation algorithm with a random element of 20%, stratified for hospital
site, age at randomisation (<70 years old versus 70 years old at ran-
domisation), WHO performance status (a score of 0 versus 1/2), nodal
involvement (negative, positive or unspecified), planned ADT and usage
(yes/no) of aspirin or other non-steroidal anti-inflammatory drugs
(NSAIDs). The randomisation algorithm was developed and maintained
centrally at the MRC Clinical Trials Unit at UCL. The trial was carried
out in accordance with Good Clinical Practice guidelines, with full regu-
latory and ethical approval.
The first efficacy results for docetaxel within the STAMPEDE [1] used
data from the initial randomisation in October 2005 to the data freeze
with follow-up to March 2015. The date of this analysis was pre-
determined by accumulation of events in the control group. In this paper,
we report on a pre-planned long-term efficacy analyses of the M1 patient
cohort but with updated results using extended follow-up data to July
2018.
Procedures
All procedures relating to administration and reporting of docetaxel as a
research treatment have been reported previously [1]. In brief, patients
were randomised to lifelong ADT with or without six cycles of docetaxel
(75mg/m2) given 3-weekly with prednisolone 5mg twice daily during
the 18-week period of therapy.
The follow-up schedule, defined in the trial protocol, involved follow-
up visits every 6weeks until 6months after randomisation, then 12weeks
to 2 years, 6months to 5 years and annually thereafter. Toxicity was
reported routinely at follow-up visits. Adverse event classification and
grades followed the National Cancer Institute Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0. Since the primary re-
port for this comparison, data on baseline metastatic burden has been
retrospectively collected where possible for UK patients blinded to treat-
ment outcomes. Metastatic burden was assessed using whole-body scin-
tigraphy and computed tomography or magnetic resonance imaging
staging scans, categorised following the definition used in the
CHAARTED trial [3], where high-burden patients had either four or
more bone metastases including one or more outside the vertebral body
or pelvis, or any visceral metastases, or both. All other patients metastatic
at baseline were categorised as having lowmetastatic burden according to
this definition.
Outcomes
Overall survival was specified as the primary efficacy outcome and
defined as time from randomisation to death from any cause. Secondary
outcomes for long-term efficacy data included: failure-free survival (FFS;
time from randomisation to the first of any: biochemical, lymph node,
distant metastatic progression or prostate cancer death); progression-
free survival (PFS; time from randomisation to the first FFS event, not
including biochemical progression); metastatic progression-free survival
Original article Annals of Oncology
2 | Clarke et al.
(mPFS; time from randomisation to either new metastases, progression
of existing metastases or prostate cancer death) and prostate cancer-
specific survival (PCSS; time from randomisation to prostate cancer
death). Biochemical progression was assessed using prostate-specific
antigen (PSA) measurements which were reported at each follow-up
visit. The lowest PSA value within the first 24 weeks after enrolment was
used to define a nadir, from which an increase of 50% and to a minimum
level of 4 ng/ml indicated biochemical progression. For a small propor-
tion of patients, PSA levels did not fall after enrolment and a nadir could
not be estimated; these patients were considered to have biochemical
progression at the date of randomisation. Patients without any event of
interest reported by the time of the data freeze were censored in the analy-
ses at the time they were last recorded in the trial as without an event.
The cause of death was assigned as prostate cancer/not prostate cancer
where possible, using a set of rules pre-specified by the Trial Management
Group’s End point Review Committee. Any deaths not meeting the pre-
specified rules were individually reviewed by a trial clinician to assign a
cause of death independent of the allocated treatment.
Statistical analysis
Sample size calculations for trial design used the nstage function in
Stata, based on a target HR of 0.75 for the primary efficacy analysis.
Long-term outcome analysis was planned for3 years after the first ana-
lysis, when there was projected to be a 40% increase in control group
deaths. For the long-term analysis by metastatic disease burden, there
was 66% and 77% power to detect a hazard ratio of 0.75 in the low and
high-burden sub-groups, respectively. This calculation used the observed
accrual and previous event rate in the control group (without reference
to any accumulating differences between arms/sub-groups).
Efficacy analyses, following intention-to-treat principles, included all
patients allocated to a trial arm. Toxicity and adverse event data are pre-
sented with patients grouped according to whether or not docetaxel
treatment was reported as having been started (29 patients randomised
to docetaxel who did not receive the drug are reported as Controls for the
purposes of comparing toxicity between the treatments). See Figure 1 for
full details of patients included in the analyses.
All time-to-event analyses followed standard survival analysis methods
using Stata (version 15.1). Median duration of follow-up period was esti-
mated using the Kaplan–Meier method with reverse-censoring of any
reported deaths. Hazard ratios were estimated from Cox proportional
hazards regression models, adjusted for minimisation factors used in the
randomisation algorithm (nodal stage, age at randomisation, WHO per-
formance score, use of aspirin/NSAIDs, planned use of SOC radiother-
apy) and stratified by time period, as defined according to the other arms
open to accrual in STAMPEDE (i.e. changes through closure or opening
of other trial arms on the platform) or SOC practice changes. Non-
parametric stratified log-rank tests were used to test for differences be-
tween the control and docetaxel groups, with stratification the same as
that of the Cox regression models. Flexible parametric models were used
to generate 5-year survival estimates, fitted using (5,5) degrees of freedom
with adjustment variables as specified above. PCSS was analysed using
Fine and Grey regression methods for competing risks analysis [17]. For
all outcomes, models were tested for evidence of non-proportional haz-
ards, and where found, interpretation of the results emphasises restricted
mean survival time (RMST), which was calculated using a t* of
120months, estimated as described previously [18]. For all statistical
tests, two-sided tests were used and 95% confidence intervals and P-val-
ues are reported. Sub-group analyses are presented for all outcomes for
metastatic burden sub-groups (low- and high-burden sub-groups).
Although our emphasis is on metastatic burden, exploratory sub-group
analyses are also presented for the primary outcome in order to give detail
on the consistency of treatment effect across baseline factors of potential
interest for this patient population: nodal status (N0, Nþ or NX),
Gleason sum score (7, 8–10 or unknown), patient age (<70 or 70)
andWHOperformance score (0 or 1–2).
Results
One thousand and eighty-six metastatic patients (724 control/
362 docetaxel) were recruited to STAMPEDE’s ‘docetaxel com-
parison’ between 05 October 2005 and 31 March 2013. The data-
set for this analysis was frozen on 13 July 2018. As reported
previously, baseline patient characteristics were well-balanced
across trial arms (Table 1). We additionally report sub-group
analyses according to metastatic burden, which was assessed
using bone scans available from 830/1086 (76%) of all recruited
patients. The patients included in these sub-group analyses were
well-balanced across arms (Table 2 and supplementary Table S1,
available at Annals of Oncology online). In addition, a comparison
of Tables 1 and 2 demonstrates that the subset of patients
included in the metastatic burden sub-group analyses was repre-
sentative of the metastatic patients in the comparison as a whole,
with the exception of the year of randomisation, where the
patients included in the metastatic burden sub-group analyses
were enrolled in the latter years of recruitment to the comparison.
Figure 1 shows a Consort diagram with full details of patient
numbers included in the analyses.
The median duration of follow-up was 78.2months (inter-
quartile range (IQR): 62.9–96.3). There were 719 deaths reported;
494/724 (68%) control patients died compared with 225/362
(62%) docetaxel patients. Control group patients had a median
survival of 43.1months and an estimated 5-year survival of 37%
(95% CI 34% to 41%), whereas patients receiving docetaxel had a
median survival of 59.1months and 5-year survival of 49% (95%
CI 44% to 54%). There was good evidence of a benefit from doce-
taxel on survival (stratified log-rank test P¼ 0.003, HR¼ 0.81,
95% CI 0.69–0.95; Figure 2A). As there was evidence (P¼ 0.016)
of non-proportional hazards in the treatment effect, the inter-
pretation of these results focuses on the difference in RMST be-
tween arms. This method showed evidence of a benefit of
docetaxel, with an estimated difference of 6.0months (95% CI
0.7–11.4) in RMST (over 120months) between groups.
There was no evidence of heterogeneity of treatment effect on
survival over metastatic burden sub-groups (interaction
P¼ 0.827). For the low-burden patients (n¼ 362, deaths¼ 166;
Figure 2C), the median survival in control was 76.7months, with
5-year survival 57% (95% CI 51% to 64%), compared with a me-
dian of 93.2months and 5-year survival of 72% (95% CI 65% to
80%) for docetaxel. Results for high-burden patients (n¼ 468,
deaths¼ 360) were similar in terms of docetaxel effect, although,
as expected, the high-burden patients generally had shorter sur-
vival time than low-burden patients (Figure 2E). Themedian sur-
vival for control was 35.2months and the 5-year survival estimate
of 24% (95% CI 20% to 29%), compared with 39.9months with
a 5-year survival of 34% (95% CI 27% to 42%) for docetaxel. The
hazard ratios were consistent in the low-burden (HR¼ 0.76, 95%
CI 0.54–1.07, P¼ 0.107) and high-burden (HR¼ 0.81, 95% CI
0.64–1.02, P¼ 0.064) sub-groups. The consistency of docetaxel
treatment effect on survival across other baseline characteristics
was examined as exploratory sub-group analyses, summarised in
Figure 3. There is no good evidence that the docetaxel effect varies
across any of the sub-groups included (nodal status, Gleason sum
score, age orWHO performance score).
There was good evidence of significant benefit for adding doce-
taxel on failure-free (HR¼ 0.66, 95% CI 0.57–0.76, P< 0.001;
Annals of Oncology Original article
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Figure 2B), progression-free (HR¼ 0.69, 95% CI 0.59–0.81,
P< 0.001; Figure 4A), metastatic progression-free (HR¼ 0.72,
95% CI 0.62–0.84, P< 0.001; Figure 4B) and PCSS (sub-
HR¼ 0.78, 95% CI 0.66–0.93, P¼ 0.005; Figure 4C).
Furthermore, the effect of treatment was consistent across meta-
static burden sub-groups (interaction P-values: FFS¼ 0.792;
PFS¼ 0.855; mPFS¼ 0.960; PCSS¼ 0.413) for other outcome
measures (Table 3).
Treatment adherence to docetaxel was reported previously [1];
all patients had completed docetaxel treatment before the first
efficacy analysis. Twenty-nine metastatic patients allocated to
Docetaxel never reported starting chemotherapy. They are
included in Control for toxicity analysis (see Figure 1) which is
summarised in Table 4 and supplementary Table S2 and Figure
S1, available at Annals of Oncology online. A comparison of tox-
icity reported across groups in the first year of follow-up shows
higher toxicity in docetaxel (42% docetaxel reported G3-5 tox-
icity versus 24% in Control). However, toxicity reports for subse-
quent follow-up, after the initial year, are balanced across groups
(27% docetaxel reported G3-5 toxicity compared with 28%
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10 355 patients randomised to STAMPEDE trial
from 5-Oct-2005 to 13-Jul-2018 (date of data
freeze for this analysis)
3988 patients randomised to STAMPEDE trial
during relevant recruitment period (5-Oct-
2005 to 31-Mar-2013)
1776 randomised to this comparison (2:1
allocation)
6367 randomised after recruitment to this
comparison had closed (on 31-Mar-2013)
2212 randomised to other research arms or
not eligible as a control for this comparison
1184 allocated standard-
of-care (control)
724 M1 standard-of-care
140 alive, data in past year
90 alive, no data in past
year
494 deaths
724 analysed for long-
term efficacy
558 had baseline metastatic
burden assessed from
scans
238 low burden
320 high burden
735 analysed for safety
753 had only standard-of-
care (724 control arm; 29
research arm)
18 excluded due to no
safety assessment
460 non-metastatic at
baseline excluded from
this analysis
592 allocated docetaxel
(research) arm
362 M1 docetaxel arm
272 had baseline metastatic
burden assessed from
scans
124 low burden
148 high burden
230 non-metastatic at
baseline excluded from
this analysis
Scans unavailable for 90
docetaxel patients
1 excluded due to no
safety assessment
74 alive, data in past year
63 alive, no data in past
year
225 deaths
362 analysed for longterm
efficacy
333 received docetaxel (0
control arm; 333 research
arm)
332 analysed for safety
Scans unavailable for 166
control patients
Figure 1. Consort diagram.
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control), with no good evidence of increased toxicity in the doce-
taxel group after the first year of follow-up. Table 5 shows some
evidence that control patients were more likely to report starting
second-line (or subsequent) treatment following disease progres-
sion, with 80% reporting starting at least one further line of treat-
ment compared with 68% for Docetaxel. The types of further
therapy reported are broadly similar between the two groups.
A sensitivity analysis was undertaken without the M1 patients
retrospectively found not to have met all of the strict protocol eli-
gibility criteria, mostly concerning a review of baseline blood
pressure measurements. Removing these 120 patients (11%) did
not change the primary outcome measure results HR¼ 0.81
(95%CI 0.68–0.96; P¼ 0.013).
Discussion
In this updated long-term analysis, the relative survival benefit
for adding docetaxel to ADT in mHNPC confirmed our previous
findings. A statistically and clinically significant improvement in
survival and a delayed time tometastatic progression was demon-
strated with the combination treatment compared with ADT
alone. Importantly, this benefit is seen irrespective of metastatic
burden, with no evidence of heterogeneity between the low and
high metastatic burden sub-groups across any outcome meas-
ures. This reinforces the principle that ADT and docetaxel can be
considered as an effective first-line treatment option for men
with mHNPC regardless of metastatic burden.
Two other trials have also evaluated the combination of doce-
taxel with ADT over ADT alone in mHNPC. The first trial,
GETUG-AFU-15, enrolled 385 patients and reported with me-
dian follow-up of 84months. This showed no clear evidence of
improvement in survival by adding docetaxel to ADT over ADT
alone (HR¼ 0.88, 95% CI 0.68–1.14, P¼ 0.3) [19]. The second
trial, CHAARTED, enrolled 790 patients and reported with me-
dian follow-up of 54months, demonstrating clear evidence of an
improvement in survival for adding docetaxel (HR¼ 0.72, 95%
CI 0.59–0.89, P¼ 0.0018) [3, 9]. STAMPEDE is the largest of the
Table 1. Baseline characteristics for all metastatic patients, by trial arm
Patient characteristic Control Docetaxel
Randomised (2 : 1 allocation) 724 100% 362 100%
Age at randomisation (years)
Median 65 65
IQR 60–71 60–70
WHO performance status
0 521 72% 270 75%
1–2 203 28% 92 25%
T stage
T0 3 <1% 1 <1%
T1 12 2% 0 0%
T2 75 10% 51 14%
T3 404 56% 197 54%
T4 163 23% 82 23%
TX 67 9% 31 9%
Nodal status
N0 242 33% 118 33%
Nþ 416 57% 211 58%
NX 66 9% 33 9%
Metastatic burdena
Low 238 33% 124 34%
High 320 44% 148 41%
Unassessed 166 23% 90 25%
Site of metastasesb
Bone 634 88% 307 85%
Liver 15 2% 6 2%
Lung 33 5% 13 4%
Nodesc 221 31% 102 28%
Other 46 6% 25 7%
Gleason sum score
7 158 22% 65 18%
8–10 480 66% 253 70%
Unknown 86 12% 44 12%
PSA
Median 102.5 97
IQR 32.8–354 40.5–340
Time from diagnosis to randomisation (days)
Median 69 73
IQR 49–92 55–95
Planned SOC RTd
Not planned 677 94% 333 92%
Planned 47 6% 29 8%
Previously treated
No 689 95% 347 96%
Yes 35 5% 15 4%
Pain from prostate cancer
Absent 553 76% 270 75%
Present 154 21% 88 24%
Unknown 17 2% 4 1%
Year of randomisation
2005 1 <1% 1 <1%
2006 28 4% 14 4%
2007 38 5% 19 5%
2008 70 10% 34 9%
2009 93 13% 45 12%
2010 111 15% 58 16%
2011 169 23% 87 24%
Continued
Table 1. Continued
Patient characteristic Control Docetaxel
2012 172 24% 85 23%
2013 42 6% 19 5%
Total 724 100% 362 100%
aCHAARTED deﬁnition.
bPatients may have had more than one site of metastases at baseline,
therefore are represented in more than one ‘site of metastases’ category.
Percentages shown are per individual site for the total patients in the
arm.
cNon-regional lymph nodes.
dPrimary site RT was not standard-of-care (SOC) for M1 patients at the
time of the trial. However, SOC RT was reported as planned for a small
proportion of patients due to clinical decisions for these individual cases
to receive RT to non-prostate locations, or due to mis-reporting of pallia-
tive RT.
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3 trials, enrolling 1086 mHNPC patients and reporting here with
median follow-up of 78months. Our long-term results for these
metastatic patients lie between those of GETUG-AFU-15 and
CHAARTED and show clear evidence of improved survival asso-
ciated with the combination of docetaxelþADT over ADT alone
(HR¼ 0.81, 95%CI 0.69–0.95, P¼ 0.009).
However, in contrast to the CHAARTED and GETUG-15 tri-
als, we found no good evidence in this study of a difference in
benefit between the high and low metastatic burden sub-groups
for survival and all other outcomemeasures. Indeed, the point es-
timate of the benefit for ‘low-burden’ patients was of ‘greater’
magnitude than that for the high-burden group. Prior sub-group
analysis conducted as part of the CHAARTED and GETUG-15
trials suggested a smaller overall survival benefit associated with
the combination of docetaxelþADT in patients with low meta-
static burden compared with high metastatic burden [10]. Based
on this, docetaxel was recommended by those authors as a first-
line option only for high but not low-burden mHNPC [11]. That
view was not universally accepted and the inherent limitations of
the previous sub-group analyses can possibly explain the discord-
ance to our new findings [14–16]. Nearly 25% of the patients
enrolled in the other two trials presented with metastatic disease
after previous radical treatment. That group of patients has a differ-
ent natural history to those presenting with de-novo M1 disease
[20, 21]. Consequently, the low metastatic burden sub-groups
in the CHAARTED and the GETUG-15 trials had fewer than 160
de-novomHNPC patients each [10]. In our updated report,95%
of patients had de-novoM1, with a total of 362 patients in the low
metastatic burden sub-group. This larger sample size provides a
stronger basis for estimating a treatment effect in this sub-group.
Furthermore, there was no evidence of a difference in benefit asso-
ciated with docetaxel with ADT over ADT alone when considering
metastatic burden (interaction P¼ 0.827). Based on these findings,
the combination of docetaxel with ADT should be a first-line treat-
ment option for newly diagnosed mHNPC patients regardless of
metastatic burden.
Our results have to be interpreted in light of more recently-
recruited trials. Since the last report, a number of other systemic
Table 2. Baseline characteristics, for the subset of 830/1086 patients
included in metastatic burden sub-group analysis, by trial arm
Patient characteristic Control Docetaxel
Randomised 558 100% 272 100%
Age at randomisation (years)
Median 65 65
IQR 60–71 62–70
WHO performance status
0 405 73% 204 75%
1–2 153 27% 68 25%
T stage
T0 1 <1% 1 <1%
T1 9 2% 0 0%
T2 56 10% 36 13%
T3 315 56% 155 57%
T4 129 23% 58 21%
TX 48 9% 22 8%
Nodal status
N0 185 33% 88 32%
Nþ 322 58% 161 59%
NX 51 9% 23 8%
Metastatic burdena
Low 238 43% 124 46%
High 320 57% 148 54%
Site of metastasesb
Bone 485 87% 226 83%
Liver 12 2% 4 1%
Lung 22 4% 12 4%
Nodesc 175 31% 78 29%
Other 38 7% 20 7%
Gleason sum score
7 118 21% 51 19%
8–10 381 68% 188 69%
Unknown 59 11% 33 12%
PSA
Median 102.5 96.8
IQR 33–338.7 37.8–348.1
Time from diagnosis to randomisation (days)
Median 69 74
IQR 50–92 56–95
Planned SOC RTd
Not planned 523 94% 252 93%
Planned 35 6% 20 7%
Previously treated
No 528 95% 261 96%
Yes 30 5% 11 4%
Pain from prostate cancer
Absent 427 77% 200 74%
Present 120 22% 69 25%
Unknown 11 2% 3 1%
Year of randomisation
2005 0 0% 0 0%
2006 0 0% 0 0%
2007 0 0% 0 0%
2008 19 3% 8 3%
2009 82 15% 39 14%
2010 105 19% 52 19%
2011 157 28% 78 29%
Continued
Table 2. Continued
Patient characteristic Control Docetaxel
2012 157 28% 78 29%
2013 38 7% 17 6%
Total 558 100% 272 100%
aCHAARTED deﬁnition.
bPatients may have had more than one site of metastases at baseline,
therefore are represented in more than one ‘site of metastases’ category.
Percentages shown are per individual site for the total patients in the
arm.
cNon-regional lymph nodes.
dPrimary site RT was not standard-of-care (SOC) for M1 patients at the
time of the trial. However, SOC RT was reported as planned for a small
proportion of patients due to clinical decisions for these individual cases
to receive RT to non-prostate locations, or due to mis-reporting of pallia-
tive RT.
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treatments such as abiraterone, apalutamide and enzalutamide
have also shown statistically and clinically significant survival
benefits over SOC alone when used as first-line agents in
mHNPC [4–7]. None of the trials using androgen receptor path-
way targeting have shown any evidence of heterogeneity of effect
by metastatic burden. Our previous analysis of patients rando-
mised contemporaneously within STAMPEDE to a docetaxel
group or an abiraterone group did not show any difference in
overall survival. Whilst that was acknowledged as under-
powered, opportunistic comparison, it remains the only direct
randomised comparison of docetaxel and abiraterone, and the
results are in keeping with both agents being valid first-line
options when combined with ADT [22].
Conclusion
This updated report, with long-term follow-up and metastatic
burden sub-group analysis, reinforces the benefits of adding
docetaxel to ADT in mHNPC. The combination treatment
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prolongs survival and improves a range of outcome measures,
including time to metastatic progression and subsequent therapy.
It should be considered as a first-line option for fit patients with
mHNPC, irrespective of metastatic burden.
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Control
(%)
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(%)
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Table 4. Worst adverse event grade reported per patient (across all CTCAE
categories) for (i) up to one year on the trial; and (ii) after one year on
the trial
Worst AE grade Up to one yeara After one yeara
Control Docetaxel Control Docetaxel
0 21 3% 0 0% 26 6% 12 5%
1 267 36% 63 19% 147 32% 65 25%
2 268 36% 128 39% 155 34% 109 43%
3 157 21% 96 29% 110 24% 63 25%
4 20 3% 44 13% 15 3% 6 2%
5 2 <1% 1 <1% 1 <1% 0 0%
No FU/SAE reported 18 n/a 1 n/a 18 n/a 1 n/a
Not on FU after one year n/a n/a n/a n/a 281 n/a 77 n/a
Totalb 753 100% 333 100% 753 100% 333 100%
aTimed from randomisation.
bTotal numbers shown for safety population, where 29 patients allocated
to the Docetaxel Group never started Docetaxel treatment and are there-
fore included in the standard-of-care (SOC) group for safety reporting.
Note that ‘missing’ data refers to patients who did not report AE data
after this point (either died or withdrawn from the trial, or not reporting
AEs after disease progression as speciﬁed in the trial protocol).
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